Recombinant Proteins Show Promise for Osteoporosis Treatment

Osteoporosis, a degenerative disease affecting millions worldwide, is characterized by a loss of bone mass, microarchitectural deterioration and a general decline in bone quality, which leads to an increased risk of fractures. As populations age, the incidence of osteoporosis rises, creating a pressing need for effective treatments. Current therapies, including antiresorptive and anabolic drugs, often come with significant side effects, prompting researchers to seek innovative solutions. Recent advancements in Biotechnology have opened new avenues for developing therapies that can potentially reverse the effects of osteoporosis and enhance bone regeneration.

A recent study explored the potential of recombinant human peptide growth factors, Bone Morphogenetic Protein-7 (rhBMP7), and Platelet-Derived Growth Factor-BB (rhPDGF-BB) in treating osteoporosis using an oophorectomized rat model. The research, led by Professor Mari Cleide Sogayar and Dr. Ana Claudia Carreira along with their team including MSc Thamara Reis, Dr. Alice Del Colletto, Luiz Silva, and Dr. Bruna Koga from the University of São Paulo, was published in the journal Biomolecules. The researchers aimed to investigate new anabolic treatments to facilitate bone mass recovery, particularly for patients unable to tolerate the current medications.

The team employed an oophorectomy-induced osteoporosis rat model to evaluate the effects of systemic administration of rhBMP7 and rhPDGF-BB. Forty female Sprague Dawley rats underwent oophorectomy surgery, and treatments commenced on the post-surgery when all animals exhibited signs of osteoporosis. The treatments were administered intravenously.

The study found that the most effective treatments were the administration of rhPDGF-BB combined with rhBMP-7 twice a week, and rhBMP-7 alone twice a week. These treatments resulted in significant increases in the bone volume fraction and trabecular number. Specifically, the combined treatment led to substantial increases in both bone volume and the number of bone trabeculae, while the BMP-7 alone treatment also resulted in marked improvements in these measures.

“Our findings suggest that the combined systemic administration of rhPDGF-BB and rhBMP-7 can partially reverse osteoporosis in this animal model,” said Professor Sogayar. “This establishes these recombinant growth factors as potential candidates for the clinical treatment of osteoporosis.”

The research team conducted a thorough analysis of the treated animals. Histological examination confirmed the development of osteoporosis in the oophorectomized rats, characterized by significant reduction in trabecular thickness and an increase in intramedullary adipocytes. The effective treatments demonstrated increased trabecular thickness and reduced disease severity, indicating potential therapeutic benefits.

The promising results from Professor Sogayar and Dr. Carreira’s study highlight the potential of rhPDGF-BB and rhBMP-7 as therapeutic agents for osteoporosis. The next step involves testing these treatments under clinical conditions to evaluate their efficacy in human patients. The findings pave the way for developing new anabolic treatments that could offer significant improvements over current osteoporosis therapies in humans.